HealthTell, Inc. Hires Gary Riordan as New Vice President of Regulatory and Quality

Home / HealthTell, Inc. Hires Gary Riordan as New Vice President of Regulatory and Quality

SAN RAMON, Calif., Feb. 8, 2017 /PRNewswire/ — HealthTell, Inc., a company developing diagnostic, prognostic and monitoring tests for complex immune mediated diseases, today announced the appointment of Gary Riordan, Vice President of Regulatory and Quality.

“I’m excited to have Gary as part of the HealthTell team,” said HealthTell CEO, Bill Colston. “We are at the point where we need to advance our quality and regulatory infrastructure. HealthTell is very fortunate to find someone with Gary’s experience and qualifications to lead this challenge.”

Mr. Riordan is a diagnostic industry veteran with over 20 years of commercialization and regulatory experience. He has held executive commercial positions at leading companies including NanoString, Accumetrics, Sequenom, PrimeraDx, and Roche Molecular Systems. Gary has successfully initiated and advanced compliant quality systems, and has a track record of successful regulatory filings through the FDA. He started his career at the FDA, where he spent six years at the Center for Biologics Evaluation and Research (CBER) as a reviewer for in vitro diagnostic tests for HIV and Hepatitis.

About HealthTell, Inc.

Founded in 2012, HealthTell is committed to empowering the next generation of medical tests and treatments for cancer, neurological, autoimmune, and infectious diseases. Our strategy is to form commercial partnerships with diagnostic and therapeutic companies and allow them access to our proprietary ImmunoSignature™ platform for their specific application. As the first and only platform capable of broadly characterizing antibody response at scale, we enable these partners to uncover new biological insights that can be used to dramatically improve healthcare. For more information, please visit: